Merck 4Q Revenues: $14.6 billion (+6%) 4Q Loss: $1.2 billion (earnings were $3.0 billion 4Q22) FY Revenues: $60.1 billion (+1%) FY Earnings: $14.5 billion (-97%) Comments: Pharmaceutical sales were $13.1 billion, up 8% driven by growth in oncology, vaccines and hospital acute care, partially offset by a decline in virology, due to COVID-19 vaccine LAGEVRIO, and diabetes. LAGEVRIO sales were down 77% due to nonrecurrence of sales in the U.K. and lower demand in Japan and Australia. JANUVIA/J...